Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Anti-5-Methylcytidine - Clone 33D3 - AnaSpec, EGT Group is pleased to offer Eurogentec’s popular monoclonal antibody, anti-5-methylcytidine (Clone 33D3) for use in epigenetics research - AnaSpec.com
AnaSpec Introduces Anti-5-Methylcytidine - Clone 33D3

 

PRZOOM - /newswire/ - Fremont, CA, United States, 2012/05/29 - AnaSpec, EGT Group is pleased to offer Eurogentec’s popular monoclonal antibody, anti-5-methylcytidine (Clone 33D3) for use in epigenetics research - AnaSpec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Purified from ascites, this IgG1 / λ isotype antibody is supplied as a 1 mg/ml solution (in PBS) and is available in three sizes (0.1 mg, 0.5 mg and 1 mg).
5-Methylcytidine (5-MeCyd) is cytosine modified by methylation on the fifth position of the cytidine ring. This modification occurs naturally in the DNA of plants and vertebrate. DNA methylation is a post-replication process involved in the establishment of genomic imprinting, in the control of gene expression and of differentiation. Alterations of DNA methylation pattern are associated with carcinogenesis. A global DNA hypomethylation is often detected in tumor tissues, associated with local hypermethylation sites. Since this antibody discriminates between the modified base, 5-MeCyd and its normal counterpart, cytosine, it is a useful tool for gene promoter methylation analysis.

The most published anti-5-Methylcytidine antibody available on the market, anti-5-Methylcyidine from Clone 33D3 can be used in applications such as Methylated DNA Immunoprecipitation (MeDIP), MeDIP-on-chip assay, immunofluorescence, flow cytometry and immunohistochemistry. Histopathological analysis of tissue samples can be performed without having to destroy cells through DNA extraction procedures.

This antibody has been used to detect alterations in the urinary excretion of nucleosides from cancer patients, to visualize the distribution of methyl-rich regions along human chromosomes, to quantify in situ differences between normal and malignant cells from peripheral blood as well as on tissue sections.

AnaSpec, EGT Group

AnaSpec, Eurogentec Group (anaspec.com) is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and qPCRs. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces Anti-5-Methylcytidine - Clone 33D3

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress
Imec Announces elPrep5 - the Newest Version of its Software Platform for DNA Analysis
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Limelon Advertising, Co.

Visit  RightITnow, Inc.







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today